Inhibition of prolyl oligopeptidase increases the survival of alpha-synuclein overexpressing cells after rotenone exposure by reducing alpha-synuclein oligomers

Dexter, 2013, Parkinson disease: from pathology to molecular disease mechanisms, Free Radic. Biol. Med., 62, 132, 10.1016/j.freeradbiomed.2013.01.018 Surguchov, 2008, Molecular and cellular biology of synucleins, Int. Rev. Cell. Mol. Biol., 270, 225, 10.1016/S1937-6448(08)01406-8 Spillantini, 1997, Alpha-synuclein in Lewy bodies, Nature, 388, 839, 10.1038/42166 Wakabayashi, 2013, The Lewy body in Parkinson's disease and related neurodegenerative disorders, Mol. Neurobiol., 47, 495, 10.1007/s12035-012-8280-y Perier, 2012, Mitochondrial biology and Parkinson's disease, Cold Spring Harb Perspect. Med., 2, a009332, 10.1101/cshperspect.a009332 Surmeier, 2007, Calcium, ageing, and neuronal vulnerability in Parkinson's disease, Lancet Neurol., 6, 933, 10.1016/S1474-4422(07)70246-6 Martinez, 2012, Toxin models of mitochondrial dysfunction in Parkinson's disease, Antioxid. Redox Signal., 16, 920, 10.1089/ars.2011.4033 Dias, 2013, The role of oxidative stress in Parkinson's disease, J. Parkinson's Dis., 3, 461, 10.3233/JPD-130230 Nakamura, 2011, Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein, J. Biol. Chem., 286, 20710, 10.1074/jbc.M110.213538 Brandt, 2008, Prolyl oligopeptidase stimulates the aggregation of alpha-synuclein, Peptides, 29, 1472, 10.1016/j.peptides.2008.05.005 Garcia-Horsman, 2007, On the role of prolyl oligopeptidase in health and disease, Neuropeptides, 41, 1, 10.1016/j.npep.2006.10.004 Männistö, 2007, Prolyl oligopeptidase: a potential target for the treatment of cognitive disorders, Drugs News Perspect., 20, 293, 10.1358/dnp.2007.20.5.1120216 Tenorio-Laranga, 2012, Four day inhibition of prolyl oligopeptidase causes significant changes in the peptidome of rat brain, liver and kidney, Biochimie, 94, 1849, 10.1016/j.biochi.2012.04.005 Di Daniel, 2009, Prolyl oligopeptidase binds to GAP-43 and functions without its peptidase activity, Mol. Cell. Neurosci., 41, 373, 10.1016/j.mcn.2009.03.003 D’Agostino, 2012, Prolyl endopeptidase-deficient mice have reduced synaptic spine density in the CA1 region of the hippocampus, impaired LTP, and spatial learning and memory, Cereb. Cortex Hannula, 2013, Prolyl oligopeptidase colocalizes with alpha-synuclein, beta-amyloid, tau protein and astroglia in the post-mortem brain samples with Parkinson's and Alzheimer's diseases, Neuroscience Savolainen, 2014, The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse, Neurobiol. Dis., 68C, 1, 10.1016/j.nbd.2014.04.003 Myöhänen, 2012, A prolyl oligopeptidase inhibitor, KYP-2047, reduces alpha-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease, Br. J. Pharmacol., 166, 1097, 10.1111/j.1476-5381.2012.01846.x Jarho, 2004, A cyclopent-2-enecarbonyl group mimics proline at the P2 position of prolyl oligopeptidase inhibitors, J. Med. Chem., 47, 5605, 10.1021/jm049503w Venäläinen, 2006, Binding kinetics and duration of in vivo action of novel prolyl oligopeptidase inhibitors, Biochem. Pharmacol., 71, 683, 10.1016/j.bcp.2005.11.029 Jalkanen, 2012, The effect of prolyl oligopeptidase inhibition on extracellular acetylcholine and dopamine levels in the rat striatum, Neurochem. Int., 60, 301, 10.1016/j.neuint.2011.12.010 Gerard, 2008, FK506 binding protein 12 differentially accelerates fibril formation of wild type alpha-synuclein and its clinical mutants A30P or A53T, J. Neurochem., 106, 121, 10.1111/j.1471-4159.2008.05342.x Barth, 2010, Autophagy: assays and artifacts, J. Pathol., 221, 117, 10.1002/path.2694 Sala, 2013, Rotenone upregulates alpha-synuclein and myocyte enhancer factor 2D independently from lysosomal degradation inhibition, Biomed. Res. Int., 2013, 846725, 10.1155/2013/846725 Van der Veken, 2012, P2-substituted N-acylprolylpyrrolidine inhibitors of prolyl oligopeptidase: biochemical evaluation, binding mode determination, and assessment in a cellular model of synucleinopathy, J. Med. Chem., 55, 9856, 10.1021/jm301060g Ebrahimi-Fakhari, 2011, Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of alpha-synuclein, J. Neurosci., 31, 14508, 10.1523/JNEUROSCI.1560-11.2011 Watanabe, 2012, p62/SQSTM1-dependent autophagy of Lewy body-like alpha-synuclein inclusions, PLoS ONE, 7, e52868, 10.1371/journal.pone.0052868 Xiong, 2011, Potential autophagy enhancers attenuate rotenone-induced toxicity in SH-SY5Y, Neuroscience, 199, 292, 10.1016/j.neuroscience.2011.10.031 Xiong, 2013, The role of autophagy in Parkinson's disease: rotenone-based modeling, Behav. Brain Funct., 9, 10.1186/1744-9081-9-13 Komatsu, 2012, p62/SQSTM1/A170: physiology and pathology, Pharmacol. Res., 66, 457, 10.1016/j.phrs.2012.07.004 Nakamura, 2013, alpha-Synuclein and mitochondria: partners in crime, Neurotherapeutics, 10, 391, 10.1007/s13311-013-0182-9 Freeman, 2013, Alpha-synuclein induces lysosomal rupture and cathepsin dependent reactive oxygen species following endocytosis, PLoS ONE, 8, e62143, 10.1371/journal.pone.0062143 Choong, 2011, Neuroprotection of alpha-synuclein under acute and chronic rotenone and maneb treatment is abolished by its familial Parkinson's disease mutations A30P, A53T and E46K, Neurotoxicology, 32, 857, 10.1016/j.neuro.2011.05.012